Hero

Celyad Provides Clinical Update and Strategic Outlook for 2018

1

Celyad Provides Clinical Update and Strategic Outlook for 2018

Celyad Announces Third Quarter 2017 Business Update

2

Celyad Announces Third Quarter 2017 Business Update

Celyad reports a first complete response in a relapsed refractory AML patient in the THINK trial

3

Celyad reports a first complete response in a relapsed refractory AML patient in the THINK trial

Celyad announces new agreements with Celdara Medical and Dartmouth College

4

Celyad announces new agreements with Celdara Medical and Dartmouth College

Celyad reports promising early results at first dose level of the solid arm of the THINK trial

5

Celyad reports promising early results at first dose level of the solid arm of the THINK trial

About Celyad

Making the Impossible Possible

Celyad is a clinical-stage biopharmaceutical that is developing next generation CAR-T NK cell-based immunotherapies for cancer treatment.

Latest News

Celyad to Host Key Opinion Leader Meeting on CAR-T Therapy for the Treatment of Blood Cancers

Celyad to Host Key Opinion Leader Meeting on CAR-T Therapy for the Treatment of Blood Cancers

Celyad Provides Clinical Update and Strategic Outlook for 2018

Celyad Provides Clinical Update and Strategic Outlook for 2018

Letter to Shareholders - December 2017

Letter to Shareholders - December 2017

Discover all news

Carousel

Social Feed

RT @pharmabe: En Europe, 20% des nouveaux médicaments et thérapies de haute technologie contre le cancer sont en cours de développement ou…

1 week ago

RT @pharmabe: En Europe, 20% des nouveaux médicaments et thérapies de haute technologie contre le cancer sont en cours de développement ou…

#PiperJaffray: Celyad cash of US$42 million; CYAD-01 Active in Solid & Hematologic Tumors

2 weeks ago

#PiperJaffray: Celyad cash of US$42 million; CYAD-01 Active in Solid & Hematologic Tumors

CAR-T cell immunotherapy named the Advance of the Year in annual #ASCO report. We’re proud to play a key role in th… https://t.co/wF0xlR9szI

2 weeks ago

CAR-T cell immunotherapy named the Advance of the Year in annual #ASCO report. We’re proud to play a key role in th… https://t.co/wF0xlR9szI

RT @pharmabe: Happy Birthday @CelyadSA #10years https://t.co/qlD29xVJQS

2 weeks ago

RT @pharmabe: Happy Birthday @CelyadSA #10years https://t.co/qlD29xVJQS

RT @pharmabe: En Europe, 20% des nouveaux médicaments et thérapies de haute technologie contre le cancer sont en cours de développement ou…

1 week ago

RT @pharmabe: En Europe, 20% des nouveaux médicaments et thérapies de haute technologie contre le cancer sont en cours de développement ou…

#PiperJaffray: Celyad cash of US$42 million; CYAD-01 Active in Solid & Hematologic Tumors

2 weeks ago

#PiperJaffray: Celyad cash of US$42 million; CYAD-01 Active in Solid & Hematologic Tumors

CAR-T cell immunotherapy named the Advance of the Year in annual #ASCO report. We’re proud to play a key role in th… https://t.co/wF0xlR9szI

2 weeks ago

CAR-T cell immunotherapy named the Advance of the Year in annual #ASCO report. We’re proud to play a key role in th… https://t.co/wF0xlR9szI

RT @pharmabe: Happy Birthday @CelyadSA #10years https://t.co/qlD29xVJQS

2 weeks ago

RT @pharmabe: Happy Birthday @CelyadSA #10years https://t.co/qlD29xVJQS